Compare MNY & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MNY | BDSX |
|---|---|---|
| Founded | 2014 | 2005 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Precision Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.5M | 53.0M |
| IPO Year | N/A | 2020 |
| Metric | MNY | BDSX |
|---|---|---|
| Price | $1.28 | $7.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $4.00 | ★ $32.50 |
| AVG Volume (30 Days) | ★ 88.7K | 57.5K |
| Earning Date | 12-05-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $69,182,746.00 | ★ $80,173,000.00 |
| Revenue This Year | $11.26 | $20.75 |
| Revenue Next Year | $20.70 | $25.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 22.29 |
| 52 Week Low | $0.55 | $3.44 |
| 52 Week High | $2.40 | $32.20 |
| Indicator | MNY | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 46.87 | 51.69 |
| Support Level | $1.28 | $7.68 |
| Resistance Level | $1.60 | $8.17 |
| Average True Range (ATR) | 0.11 | 0.66 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 13.51 | 55.68 |
MoneyHero Ltd is a personal finance aggregation and comparison company in Greater Southeast Asia. The firm is involved in the operation of online financial comparison platforms and related services for credit cards, personal loans, mortgages, insurance, and other financial products, connecting the providers of these products with well-matched and ready-to-transact consumers and generating revenue directly from these providers for placing their products on its platforms and providing insurance brokerage, marketing and events-related services. Geographically it operates in Singapore, Hong Kong, Taiwan, Malaysia and the Philippines.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.